|
|
|
STOP THE CLOT
Hiroshi Okamoto of the Central Pharmaceutical Research Institute, JT Inc, Takasuki, Osaka, Japan, and colleagues have identified what could be a potent drug to prevent atherosclerosis. As they explain in this week's Nature (Vol. 406, Issue 6792, July 13, 2000), the compound, catchily named 'JTT-705', inhibits the protein 'CEPT'. The role of CEPT has been hitherto unclear, but the researchers show that, by influencing the lipid make-up of blood, it may contribute to the narrowing and hardening of blood vessels that constitutes atherosclerosis. In cholesterol-fed rabbits, they report that JTT-705 brings about beneficial changes in blood HDL-C and LDL-C - sometimes called 'good cholesterol' and 'bad cholesterol', respectively - that "may be reasonably extrapolated to predict the changes in plasma lipids in humans treated with this drug," Okamoto's group speculates. CONTACT: Hiroshi Okamoto tel +81 726 81 9700, fax +81 726 81 9722,
e-mail ye6h-okmt@asahi-net.or.jp (C) Nature press release.
Message posted by: Trevor M. D'Souza
|
|
Variants Associated with Pediatric Allergic Disorder
Mutations in PHF6 Found in T-Cell Leukemia
Genetic Risk Variant for Urinary Bladder Cancer
Antibody Has Therapeutic Effect on Mice with ALS
Regulating P53 Activity in Cancer Cells
Anti-RNA Therapy Counters Breast Cancer Spread
Mitochondrial DNA Diversity
The Power of RNA Sequencing
‘Pro-Ageing' Therapy for Cancer?
Niche Genetics Influence Leukaemia
Molecular Biology: Clinical Promise for RNA Interference
Chemoprevention Cocktail for Colon Cancer
more news ...
|